ArticleJournal of clinical pathology2003
Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features.
Article in Journal of clinical pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Prognostic and clinicopathological significance of mucin family members expression in gastric cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis.Disease markers · 2016Pooled it
- Prognostic value of Muc5AC in gastric cancer: A meta-analysis.World journal of gastroenterology · 2015Pooled it
- Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysis.PloS one · 2026Article
- The Role of MUC1 in Gastric Cancer Development.Cancers · 2025Review
- MUC3A promotes the progression of cholangiocarcinoma through the MAPK/ERK pathway.Discover oncology · 2025Article
- The role of gastric mucins and mucin-related glycans in gastric cancers.Cancer science · 2024Review
- The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review.Cancers · 2023Review
- Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.Cancer letters · 2023Review
- Article
- Whole-exome sequencing reveals rare genetic variations in ovarian granulosa cell tumor.Bosnian journal of basic medical sciences · 2022Article
- Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA.Canadian journal of gastroenterology & hepatology · 2021Article
- The Roles of Transmembrane Mucins Located on Chromosome 7q22.1 in Colorectal Cancer.Cancer management and research · 2021Review
- MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.International journal of biological sciences · 2021Article
- MUC3A promotes non-small cell lung cancer progression via activating the NFκB pathway and attenuates radiosensitivity.International journal of biological sciences · 2021Article
- Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study.Frontiers in oncology · 2021Article
- The role of mucin-educated platelet activation in tumor invasiveness: An unfolding concern in the realm of cancer biology.BioMedicine · 2017Article
- MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis.Oncotarget · 2017Article
- Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsSeveral studies have reported conflicting and inconclusive results concerning the clinical relevance of mucin expression in gastric carcinoma. This study investigated the correlations between aberrant expression of mucins in gastric carcinoma and patient clinicopathological features.
methodsThe expression of MUC1, MUC2, MUC3, MUC5AC, and MUC6 was investigated immunohistochemically in gastric carcinoma (n = 46) in relation to patient clinicopathological features.
resultsAll normal gastric mucosa samples expressed MUC1, MUC5AC, and MUC6. MUC1, MUC2, MUC3, MUC5AC, and MUC6 were expressed in 29, 31, 30, 18, and 21 of the 46 cases of gastric carcinoma, respectively. The number of cases expressing MUC1 was significantly higher (p < 0.01) in patients with a small tumour size (>/= 5 cm) and in patients in clinical stages I-II, compared with clinical stages III-IV (p < 0.05). Expression was significantly lower (p < 0.05) in patients exhibiting metastasis. The number of cases expressing MUC3 was significantly higher in patients in clinical stages III-IV (p < 0.05), and in those with serosal invasion (p < 0.05) or metastasis (p<0.01). No significant relations were found between MUC2, MUC5AC, MUC6, and clinical stage, metastasis, or tumour size.
conclusionsMembrane bound mucins MUC1 and MUC3 appear to be associated with the development of gastric carcinoma. Patients who maintained high immunoreactivity for anti-MUC1 antibody had a better prognosis, whereas those with an increase in anti-MUC3 immunoreactivity had a poorer prognosis, as judged by tumour size, serosal invasion, and metastasis. However, no correlation was found between MUC2, MUC5AC, or MUC6 and clinical prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.